 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase II Combination REOLYSIN®/Radiation Therapy Trial - United Kingdom In December 2006, Oncolytics announced that it had commenced enrolment in a Phase II clinical trial investigating the anti-tumour effects of intratumoural administration of REOLYSIN® in combination with low-dose radiation in patients with advanced cancers. The trial is an open-label, single-arm, multi-centre Phase II study of REOLYSIN® delivered via intratumoural injection to patients during treatment with low-dose radiotherapy. The primary objective of the trial is to assess the anti-tumour activity of the combination of REOLYSIN® and low dose radiotherapy in treated and untreated lesions. Secondary objectives include the evaluation of viral replication, immune response to the virus and to determine the safety and tolerability of intratumoural administration of REOLYSIN® in patients with advanced cancers who are receiving radiation treatment. See related press releases and documents: December 22, 2006 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial July 18, 2005 - Oncolytics Biotech Inc. Announces Approval for Phase II U.K. Clinical Trial Investigating REOLYSIN® in Combination with Radiation Therapy |
|
|||||||||||
 |
|
 |